share_log

Needham Maintains Buy on AtriCure, Lowers Price Target to $44

Needham Maintains Buy on AtriCure, Lowers Price Target to $44

Needham維持對AtriCure的買入,將目標股價下調至44美元
Benzinga ·  01/04 06:27

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $49 to $44.

尼德姆分析師邁克·馬特森維持AtriCure(納斯達克股票代碼:ATRC)的買入並將目標股價從49美元下調至44美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論